Clinical trials: Liver Cirrhosis
Primary Biliary Cirrhosis
Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
Nalfurafine hydrochloride is a selective kappa-opioid receptor agonist developed in Japan, and in May 2015 the use of nalfurafine hydrochloride was officially approved in Japan for pruritus in patients with chronic liver diseases…
- Trial name
- NCT02659696
- Where
- Japan
- Volunteers
- 44 people
- Sponsor
- Teikyo University
Liver Cirrhosis
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
The investigators will investigate the usefulness of biannual ultrasonography versus annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in single arm patients.
- Trial name
- MAGNUS-HCC (NCT02551250)
- Testing
- annual noncontrast MRI, biannual ultrasonography
- Where
- 6 sites in South Korea
- Volunteers
- 211 people
- Sponsor
- JOON-IL CHOI
MASH, MASLD
Global Research Initiative for Patients Screening on MASH
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe…
- Conditions
- MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
- Trial name
- GRIPonMASH (NCT05651724)
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 10,000 people
- Sponsor
- Julius Clinical
Endoscopic Variceal Band Ligation
Comparison of Rabeprazole and Vonoprazan in the Prevention of Post-endoscopic Variceal Ligation Ulcer in Patients With Cirrhosis
The study aims to to evaluate Vonoprazan effectiveness in prevention of post endoscopic variceal ligation (EVL) ulcer and its related bleed in comparison to Rabeprazole.
- Trial name
- NCT07608536
- Testing
- Vonoprazan, Rabeprazol
- Where
- India
- Volunteers
- 300 people
- Sponsor
- King George's Medical University
Cirrhosis, Cirrhotic Cardiomyopathy
Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset of complications in liver disease.
- Conditions
- Cirrhosis, Cirrhotic Cardiomyopathy, Cardiac Remodeling
- Trial name
- CARE Cirrhosis (NCT01676285)
- Testing
- Metoprolol succinate
- Where
- Brazil
- Volunteers
- 125 people
- Sponsor
- University of Sao Paulo
Hepatic Encephalopathy, Cirrhosis
Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy
To assess whether albumin administration after an episode of hepatic encephalopathy (≥ grade II) improves survival at 90 days (mortality endpoint treated as a composite endpoint death and/ or liver transplantation).
- Trial name
- BETA (NCT02401490)
- Testing
- Human albumin
- Where
- 7 sites in Spain
- Volunteers
- 128 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Alcoholic Cirrhosis
National Cohort of Uncomplicated Alcoholic Cirrhosis
Hepatocellular carcinoma (HCC) is a major public health problem, whose incidence is increasing in developed countries and is the leading cause of death in patients with cirrhosis.
- Trial name
- CIRRAL (NCT01213927)
- Where
- France
- Volunteers
- 709 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Overt Hepatic Encephalopathy
A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.
The goal of this trial is to learn if drugs in group A, B, C and D works to treat reversal of grades in people with overt hepatic encephalopathy. It will also provide information regarding safety of drugs in group A, B, C and D.
- Trial name
- ARGO-HEC (NCT07037394)
- Testing
- Probiotic plus lactulose, Rifaximin plus lactulose, L-ornithine-L-aspartate plus latulose
- Where
- Pakistan
- Volunteers
- 252 people
- Sponsor
- Qurratul Ain Jamil
Cirrhosis, Hepatocellular Carcinoma
Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance
The purpose of this study is to investigate clinical feasibility of annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in high-risk group, in comparison with biannual ultrasonography.
- Trial name
- NCT02854241
- Testing
- Biannual ultrasonography, Annual noncontrast liver MRI, Contrast enhanced liver CT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Hepato Cellular Carcinoma, Cirrhosis
PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)
Chronic liver diseases affect 1.5 billion people worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally.
- Conditions
- Hepato Cellular Carcinoma, Cirrhosis, Autonomic Nervous System, Central Nervous System
- Trial name
- PSYLIVER-PILOT (NCT07393074)
- Testing
- Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation., Self-administered questionnaires to assess psycho-behavioral traits, Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night.
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Portal Hypertension, Cirrhosis, Liver
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Hepatic venous pressure gradient (HVPG) is an invasive test and requires technical skills of the operator and specialized instruments.
- Trial name
- NCT04121520
- Testing
- Questionnaire
- Where
- 10 sites in Brazil, China and 5 more
- Volunteers
- 200 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Intrahepatic Cholangiocarcinoma (Icc)
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.
- Trial name
- NCT06721286
- Testing
- Teripalimab, Gemcitabine + Cisplatin, Surgery
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatopulmonary Syndrome, Liver Cirrhosis
Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
The most common observed cause of gas exchange abnormalities and hypoxemia in cirrhosis is the hepatopulmonary syndrome (HPS) with a reported prevalence of 20-47% in patients with hepatic impairment and cirrhosis.
- Trial name
- NCT01518595
- Testing
- bosentan
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Medical University of Vienna
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cirrhosis
Changes in Lab and Ultrasonography After Endoscopic Varisceal Treatment
laboratory and ultrasongraphicc changes after endoscopical varices treatment
- Trial name
- NCT03269786
- Testing
- Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC), biannual ultrasonography
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Cirrhosis； Tumor
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
Quantitative MRI scanning parameters such as T1 mapping, T2 mapping, T1ρ, and elastography are used, combined with clinical and laboratory indicators, to predict the risk of liver cancer in patients with cirrhosis.
- Trial name
- NCT06060769
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Cirrhosis, Coagulopathy
Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction
The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood products in preventing bleeding after teeth extraction…
- Trial name
- NCT00816127
- Testing
- Desmopressin, blood transfusion
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Chronic Hepatitis C, Chronic Hepatitis B
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC).
- Trial name
- ROLFH (NCT01831037)
- Testing
- Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
- Where
- 4 sites in United States, Canada
- Sponsor
- University of Arkansas